Ironwood Pharmaceuticals
IRWD
199 hedge funds and large institutions have $520M invested in Ironwood Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 64 increasing their positions, 47 reducing their positions, and 18 closing their positions.
31,809% more call options, than puts
Call options by funds: $39.2M | Put options by funds: $123K
211% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 18
167% more capital invested
Capital invested by funds: $195M → $520M (+$325M)
36% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 47
20% more funds holding
Funds holding: 166 → 199 (+33)
3.54% more ownership
Funds ownership: 91.52% → 95.06% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$3.32M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.26M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.02M |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$3M |
| 5 |
Lazard Asset Management
New York
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$7.16M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$2.92M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.7M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$1.29M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.09M |
IRWD Hedge Fund Activity: Q4 2025 in Review
199 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2025, worth a combined $520M — up 167% from $195M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new IRWD positions and 18 closed out — a net gain of 38 holders — while 64 added to existing stakes and 47 trimmed.
The largest buyer was Marshall Wace, adding an estimated $3.32M. The largest seller was Kynam Capital Management, exiting entirely with an estimated $7.16M sold.
- 199 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2025, up from 166 in Q3 2025.
- Funds reported $520M of Ironwood Pharmaceuticals stock for Q4 2025, up 167% quarter-over-quarter.
- 56 funds opened new Ironwood Pharmaceuticals positions in Q4 2025 and 18 closed out, a net change of +38 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2025 was Marshall Wace, an estimated $3.32M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2025 was Kynam Capital Management, an estimated $7.16M sold.
Based on aggregated 13F filings for Q4 2025.